Takeda changes drug name

DEERFIELD - Takeda Pharmaceuticals North America Inc. announced that Kapidex will be marketed in the United States under the new product trade name Dexilant (dexlansoprazole). The product is used to treat heartburn associated with symptomatic non-erosive gastroesophageal reflux disease, the healing of erosive esophagitis and the maintenance of healed erosive esophagitis. After receiving reports of dispensing errors between KAPIDEX and the products Casodex and Kadian, Takeda, in coordination with the U.S. Food and Drug Administration, determined that, in the interest of patient safety, a name change would be the best way to minimize future medication errors with Kapidex.